Foradil, Spiriva Labeling Will Be Revised To Highlight "For Inhalation Only"
This article was originally published in The Pink Sheet Daily
Executive Summary
Crowded labeling on unit-dose packages of Schering's Foradil Aerolizer and Pfizer/Boehringer's Spiriva HandiHaler fail to prominently highlight the capsules are for inhalation use. FDA is advising health care workers to warn patients against accidentally swallowing the asthma/COPD products after 30 cases of misadministration.
You may also be interested in...
Schering Foradil Detail Aid Implies Overly Broad Asthma Claim, FDA Says
Marketing material also "fails to reveal important risk information" about the bronchodilator, the ad division letter states. Schering says the aid was used for a specific managed care audience and was discontinued earlier in the year.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.